
By Ruth Hill R.N.
Marijuana rescheduling opponents requested to reopen an ongoing hearing on the Trump administration’s proposed reform of the HEMP Law. The rescheduling opponents sought new testimony and discovery. DEA Chief Administrative Law Judge Derek Julius said that some of the information that cannabis opponents want is “immaterial for the narrow purpose of this hearing. Other information will be explored” by participant’s questioning of witnesses during the hearing.
DEA Judge Kerek Julius has rejected the request, but he is allowing to be entered into the record and is inviting parties to submit additional briefs. The watchdog agency’s review found, among other things that DEA “does not have any policies or procedures regarding how its staff are to conduct evaluations or schedule substances. The Food and Drug Administration within the Department of Health and Human Services (HHS) “does not have policies or procedures specifying how its staff are to conduct evaluations or develop scheduling recommendations for substances.
“Requests for further briefing on these issues beyond the replies allowed above are disfavored,” Julius said. “The Motion to Admit the GAO Report is GRANTED. This matter remains STAYED until the time for briefing is closed; the stay will expire by its own terms at the conclusion of this briefing schedule.”
Attorney General Todd Blanche in April issued an order that immediately reclassified state-licensed medical cannabis, as well as marijuana products approved by the Food and Drug Administration (FDA) from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Under a separate order he signed, the DEA hearing was held in June and July to consider more comprehensively moving marijuana to Schedule III.
“The Government is not putting forth any evidence to suggest that marijuana is not dangerous. All controlled substances by definition are dangerous,” James Schwartz, a DEA attorney, said on the opening day of the hearing, according to the transcript. “That is why they are scheduled in the first place. However, controlled substances must be evaluated by the risks they pose balanced with the medical use they provide.”
“The proposed rule, the supporting documents, and the Government witnesses will establish that marijuana has a currently accepted medical use,” he said. “With that determination, marijuana can no longer remain in Schedule I.”
“Currently there are over 30,000 practitioners treating more than six million patients in 43 U.S. jurisdictions,” DEA said. “Such practices demonstrate that there is no longer a lack of accepted safety for use of marijuana under medical supervision, and as such, marijuana does not fulfill the requirements of being a Schedule I substance.”
It also said that there is “substantial evidence sufficient to show that marijuana’s abuse and dependency profiles better align with Schedule III substances than Schedule II” or Schedule I. “The vast majority of individuals who use marijuana do so in a manner that does not result in dangers to themselves or to their communities.” In conclusion, DEA asked the judge overseeing the hearing to “expeditiously recommend” that marijuana be transferred from Schedule I to Schedule III.
During the hearing, DEA officials charged with defending the cannabis rescheduling proposal highlighted testimony on marijuana’s medical benefits and its relative safety compared to other substances such as alcohol and opioids. That included appearances from a Food and Drug Administration (FDA) scientist and a medical doctor from New Hampshire who detailed how medical marijuana provides relief to pain patients and can serve as an alternative to opioids.
Several lawsuits challenging the current marijuana rescheduling process have been consolidated by a federal appeals court. Those pieces of litigation against the cannabis reform have been filed by state attorneys general, marijuana legalization opponents, and a cannabis-focused biopharmaceutical corporation.
The U.S. Court of Appeals for the District of Columbia Circuit recently rejected a drug testing industry association and a pharmaceutical company’s request to block the Trump administration from moving forward with cannabis rescheduling while the litigation is considered. The parties have jointly filed a proposed briefing schedule for the legal dispute. A congressional committee recently voted to block federal officials from taking further steps to carry out cannabis rescheduling,
During this election cycle, voters should ask candidates what they think about reforming cannabis. Activism by medical marijuana users is the only way reform will happen.
Send comments to hilruth@gmail.com











